Search

everythinglearnresearchcommunity

for

Search:↓

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.

Aging reduces skin cell renewal and defense against germs due to TGFbeta, but blocking TGFbeta could help restore these functions.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

PRC1 influences skin stem cell development by both turning genes on and off, affecting hair growth and skin cell types.

A patch made from human lung fibroblast material helps heal skin wounds effectively, including diabetic ulcers.

Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.

Upadacitinib may effectively treat alopecia areata without side effects.

Gray hair can potentially be reversed, leading to new treatments.

Ruxolitinib treatment may cause eyelash growth.

Several new treatments for different types of hair loss show promise in improving patient quality of life.

Upadacitinib improved multiple immune-related conditions in one patient.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Cancer treatments often cause skin, nail, and hair problems.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Personalized treatments for hair loss focus on specific genetic and biological pathways.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Blocking the prolactin receptor might help treat various diseases, but more research is needed.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.

Rituximab can cause skin issues, but baricitinib may help improve them.

Genetics can help tailor treatments for male pattern hair loss, improving outcomes like stabilization or modest regrowth.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.

Erythrina subumbrans leaves may help treat hair loss.

The current understanding of frontal fibrosing alopecia involves immune, genetic, hormonal factors, and possibly environmental triggers, but more research is needed for effective treatments.

Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.